Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705)

Abstract

Background: Severe fever and thrombocytopenia syndrome (SFTS) is an acute illness with a high mortality (16.2–29.1%). Unfortunately, there is no specific cure or vaccine for SFTS. Methods: In this open-label study, two patients with SFTS were treated with favipiravir, a new antiviral drug. Results: Patients had a sustainable virologic, immunologic and symptomatic recovery. Conclusions: Favipiravir may be a prosiming drug for the treatment of SFTS.